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ntegrins, matrix metalloproteases (MMPs), and the cy-
tokine TGF-
 

 
 have each been implicated in homeostatic
cell behaviors such as cell growth and matrix remodeling.
TGF-
 

 
 exists mainly in a latent state, and a major point of
homeostatic control is the activation of TGF-
 

 
. Because the
 
latent domain of TGF-
 

 
1 possesses an integrin binding
motif (RGD), integrins have the potential to sequester latent
TGF-
 
 
 
(SLC) to the cell surface where TGF-
 

 
 activation
could be locally controlled. Here, we show that SLC binds
Î
 
to 
 

 
v
 

 
8, an integrin expressed by normal epithelial and
neuronal cells in vivo. This binding results in the mem-
brane type 1 (MT1)-MMP–dependent release of active
TGF-
 

 
, which leads to autocrine and paracrine effects on
cell growth and matrix production. These data elucidate a
novel mechanism of cellular homeostasis achieved through
the coordination of the activities of members of three
major gene families involved in cell–matrix interactions.
 
Introduction
 
Cellular homeostasis is maintained in the organism through
the correct responses to extra-, intra-, and intercellular signals
(Potter, 1974). Imbalances in these signals can result in
disruption of cellular homeostasis, leading to changes in cell
mass and/or tissue organization. The cellular homeostatic
machinery consists of secreted, cell surface, and intracellular
molecules that together maintain cellular differentiation and
the balance between quiescence and entry into the cell cycle
(Lord, 1988). Homeostasis is regulated through the control
of cell proliferation mediated through cell–extracellular
matrix interactions in concert with growth-promoting and
inhibitory cytokines (Giancotti, 1997; Schwartz, 1997). A
growth inhibitory cytokine of particular importance in tissue
homeostasis is the multifunctional cytokine TGF-
 

 
 (Lord,
 
1988). The important role of TGF-
 

 
 in homeostasis is il-
lustrated by the fact that TGF-
 

 
1–deficient mice develop
epithelial hyperplasias (in addition to lethal multiorgan in-
flammation) within weeks after birth (Shull et al., 1992;
Crawford et al., 1998).
TGF-
 

 
1 is normally maintained in a latent or inactive
state by the noncovalent association of the bioactive peptide
 
of TGF-
 

 
1 with its NH
 
2
 
-terminal propeptide, latency-
associated peptide (LAP)*-
 

 
1 (Munger et al., 1997). There-
fore, normal TGF-
 

 
 function is thought to be largely
controlled by its activation from the latent state, a process
that is not understood completely (Munger et al., 1999).
However, recent evidence suggests that cell surface mole-
cules or secreted extracellular molecules can activate TGF-
 

 
.
Specifically, the integrin 
 

 
v
 

 
6 and the secreted extracellular
matrix molecule thrombospondin (TSP)-1 have been impli-
cated in activation of TGF-
 

 
1 through nonproteolytic
mechanisms (Crawford et al., 1998; Munger et al., 1999).
In addition, plasmin or the cell surface localization of matrix
metalloprotease MMP-9 by CD44 has been proposed to
lead to activation of TGF-
 

 
 through proteolytic degradation
of LAP-
 

 
1 and LAP-
 

 
2, respectively (Lyons et al., 1990; Yu
and Stamenkovic, 2000). Although these mechanisms may
be important to activation of TGF-
 

 
, particularly in re-
sponse to injury (Jirtle et al., 1991; Munger et al., 1999;
Murphy-Ullrich and Poczatek, 2000) or during neoplastic
progression (Yu and Stamenkovic, 2000), they individually
do not explain the activation of TGF-
 

 
1 in normal tissues.
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Indeed, mice deficient in TSP-1 (Crawford et al., 1998),
plasminogen (Bugge et al., 1995), CD44 (Protin et al.,
1999), or 
 

 
v
 

 
6 (Munger et al., 1999) are all born viable and
are able to reproduce, in marked contrast to the uniform le-
thality of TGF-
 

 
1–null mice (Shull et al., 1992).
The propeptide of TGF-
 

 
1, LAP-
 

 
1, contains an RGD
motif that is recognized by a subset of integrins sharing in
common the 
 

 
v integrin subunit (Munger et al., 1998).
Thus, three of the five 
 

 
v integrins, 
 

 
v
 

 
1, 
 

 
v
 

 
5, and 
 

 
v
 

 
6,
have been shown to bind to LAP-
 

 
1, and of these only
 

 
v
 

 
6 can mediate TGF-
 

 
 activation (Munger et al., 1998,
1999). Recently, evidence suggests that 
 

 
v
 

 
6-mediated acti-
vation of TGF-
 

 
1 plays an important role in response to in-
jury (Munger et al., 1999). Of the two remaining 
 

 
v inte-
grins, 
 

 
v
 

 
3 does not bind to LAP-
 

 
1 or mediate activation
of TGF-
 

 
1 (Munger et al., 1998), and 
 

 
v
 

 
8 has not been
investigated since, until recently, a system has not been
available to study its function (Cambier et al., 2000). The
Figure 1. v8 binds to LAP-1 in an 
RGD- and cation-dependent fashion. 
(a) N-octylglucoside lysates from 125I-cell 
surface-labeled 8-expressing HT1080 
cells (1 ml) were passed over two identical 
LAP-1–Sepharose columns (1 ml) and 
washed with 12 ml of wash buffer 
(shown in lanes 1, 2, and 3 are the 4th, 
11th and 12th wash fractions). One 
column was eluted with 1-ml fractions 
containing 10 mM EDTA (fractions 4–8), 
and the other column was eluted with 
1-ml fractions containing 1 mg/ml 
GRGESNK (lanes 1’–3’) or 1 mg/ml 
GRGDSNK (lanes 4’–7’). Samples were 
resolved by 7.5% SDS-PAGE under non-
reducing conditions and visualized by 
autoradiography. (b) EDTA and RGD 
elution fractions were immunoprecipitated 
with anti-8 (14E5) and compared with 
anti-v (L230) and anti-8 (14E5) 
immunoprecipitations from cell lysates. 
The migration of the MW markers is 
shown on the left, and the expected mi-
gration of the v (150 kD) and 8 (90 
kD) subunits is shown on the right. Sam-
ples were resolved by 7.5% SDS-PAGE 
under nonreducing conditions and 
visualized by autoradiography. (c) 35S 
metabolically labeled, (Translabel and 
ICN Biomedicals) truncated secreted 
v8-AP fusion protein was applied to a 
0.5-ml column of LAP-1–Sepharose, 
washed sequentially with six fractions of 
wash buffer (lane 1, last wash fraction), 
and then eluted with 1 mg/ml GRGDSPK 
(lanes 2–6). On the left are the migra-
tions of the MW markers, and on the 
right are the expected migrations of the 
truncated v (140 kD) and the truncated 
8-AP (130 kD) subunits. Samples were 
resolved by 10% SDS-PAGE under non-
reducing conditions and visualized by 
autoradiography. (d) Supernatant con-
taining secreted truncated v8 with a 
COOH-terminal AP tag (AP-v8) was 
applied to wells of a 96-well plate 
coated with either LAP-1 (10 g/ml) 
containing the RGD or the RGE binding 
motif or with VN (100 g/ml) in the presence or absence of an anti-8–blocking monoclonal antibody, 37E1. Specific binding was determined 
colorimetrically. An asterisk indicates increased binding of receptor to LAP (RGD) compared with antibody-treated or LAP (RGE) controls 
(p  0.001). (e) Binding affinity of v8 for LAP-1 was determined using concentrated AP-v8 and LAP-1–Sepharose (1fM LAP-1/bead). 
Receptor concentration was determined using purified placental AP (Applied Biosystems) as a standard. Dilutions of AP-8 were incubated 
under equilibrium-binding conditions (overnight at 4C) with 10 l LAP-1–Sepharose. Bound receptor was determined by luminescence 
using a CSPD substrate (Tropix; Applied Biosystems). (f) Adhesion of 8-expressing versus mock-transduced HT1080 cells to LAP-1 (LAP) 
and SLC-coated wells of a 96-well plate. Cells (5  104/well) were applied to each well, and after incubation for 1 h at 37C unbound cells 
were removed by centrifugation. Absorbance (A595) after staining with Crystal violet is shown on the right. *p  0.05; **p  0.01.
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v8 integrin is of particular interest, since it has been iden-
tified recently as an epithelial growth inhibitory molecule
(Cambier et al., 2000). v8 is expressed in the normal hu-
man airway epithelium but is lost in its malignant counter-
part, suggesting a role in epithelial homeostasis (Cambier et
al., 2000). Furthermore, heterologous expression of v8
inhibits lung carcinoma cell growth both in vivo and in vitro
(Cambier et al., 2000). Since v8 and TGF-1 are coex-
pressed in normal tissues, such as the human airway (Craw-
ford et al., 1998; Cambier et al., 2000), we considered the
possibility that v8 may participate in the maintenance of
airway homeostasis through activation of TGF-.
In this article, we demonstrate a novel mechanism of cell
growth regulation mediated by activation of TGF-1 via the
integrin v8. We show that v8 can bind LAP-1 and
that the consequence of this interaction is activation of
TGF-1. This mechanism of activation of TGF-1 differs
from other reported mechanisms because it is regulated
through the coordinated interactions of integrins, TGF-,
and MMPs on the cell surface. Furthermore, we show that
when lung cancer cells are reconstituted with v8, which is
normally present on the epithelial cells from which they are
derived, growth is now inhibited by TGF-1. These data
provide novel insights into the mechanisms underlying cel-
lular homeostasis.
Results
The integrin v8 binds with high affinity to the RGD 
site of recombinant LAP-1
To determine if v8 can bind to the RGD-containing
LAP-1, we performed affinity chromatography using sur-
face radiolabeled v8 and immobilized LAP-1 (Fig. 1 a).
Two bands of the appropriate kD for the v and 8 sub-
units (150 and 90 kD, respectively) bound to immobilized
LAP-1 in a divalent cation-dependent fashion as shown by
elution with EDTA (Fig. 1 a, lanes 4–8). This binding was
also dependent on the RGD sequence of LAP-1 as demon-
strated by the inability of RGE (Fig. 1 a, lanes 1–3) and
the ability of RGD to elute v8 (Fig. 1 a, lanes 4–7). The
identity of the v and 8 subunits in the elution fractions
was confirmed by immunoprecipitation (Fig. 1 b). Anti-8
antibodies immunoprecipitated 150- and 90-kD bands from
the RGD and EDTA elution fractions, which comigrated
exactly with the two bands immunoprecipitated with anti-
v and anti-8 antibodies from cell lysates (Fig. 1 b, RGD,
EDTA, and LYSATE). Immunoprecipitations of the elution
fractions using antibodies to the other RGD binding inte-
grins present on HT1080 cells, namely v5 and 51,
failed to detect any proteins (unpublished data). To measure
the relative ability of truncated v8 to bind to LAP-1 and
vitronectin (VN), the only other known ligand for v8
(Nishimura et al., 1994), we developed solid phase binding
assays for v8–ligand interactions using alkaline phos-
phatase (AP)-tagged v8 (AP-v8). The ability of AP-
v8 to bind to immobilized LAP-1 was confirmed by
metabolic labeling and affinity chromatography (Fig. 1 c).
Two bands of the appropriate molecular weight for the trun-
cated v (140 kD) and 8-AP (130 kD) subunits were
eluted by RGD peptide (Fig. 1 c). No other metabolically
labeled proteins from the cell supernatants were shown to
bind to LAP-1 by this method (Fig. 1 c). In solid phase as-
says, considerably more AP-v8 bound to wells coated
with LAP-1 (10 g/ml) than to wells coated with VN (100
g/ml) (Fig. 1 d). AP-v8 did not bind to a mutant form
of LAP (LAP [RGE]) with a single amino acid substitution
in the integrin recognition sequence (Fig. 1 d) and was com-
pletely eluted by either RGD (1 mg/ml) or EDTA (10 mM)
(unpublished data). Furthermore, v8 binding was almost
completely inhibited by the monoclonal antibody 37E1,
specific to 8 (Fig. 1 d). The affinity of AP-v8 for LAP-
1–Sepharose was determined by saturation binding experi-
ments. AP-v8 bound to LAP-1 with high affinity (Kd
13 pM) with binding saturation reached at 50% ligand
occupancy (Fig. 1 e, Bmax: 0.5 fM/1.0 fM LAP-1). Scat-
chard analysis revealed a single high affinity state of AP-
v8, consistent with other reports that secreted v inte-
grins are expressed in a constitutively active affinity state
(Nishimura et al., 1994; Weinacker et al., 1994). In contrast
to the high affinity of AP-v8 for LAP-1, the affinity of
AP-v8 for VN, the only other known ligand for v8
(Nishimura et al., 1994), was too low to be determined us-
ing this assay (unpublished data). Thus, v8 binds prefer-
entially to LAP-1 with high affinity, and this binding is
both RGD and divalent cation dependent.
To determine if v8 expressed on the cell surface could
bind latent TGF- (SLC) under physiologic conditions, we
Table I. Expression of integrin subunits in cell lines used in Fig. 2
Mean fluorescence intensity (	SE) staining
Cell line Vector 8 1 3 5 6 v 5 PBS
HT1080 8 124 	 5*** 1776 	 121 23 	 1 175 	 4** 8 	 1 523 	 49 40 	 4 4 	 0
Mock 10 	 4 1372 	 424 18 	 3 251 	 13 8 	 1 427 	 21 68 	 32 5 	 1
SW480 
8 91 	 13*** 504 	 139 7 	 1 119 	 17* 7 	 2 473 	 45 53 	 27 6 	 1
Mock 6 	 1 386 	 109 25 	 3 236 	 205 12 	 5 757 	 70 25 	 1 5 	 1
H647
8 100 	 5*** 580 	 52 11 	 3 56 	 22 60 	 14 561 	 35 ND 9 	 4
Mock 6 	 1 671 	 106 9 	 1 46 	 35 62 	 29 283 	 144 ND 9 	 3
TMLC
8 30a NDb NDb NDb NDb NDb NDb 4a
Mock 5a NDb NDb NDb NDb NDb NDb 4a
aRepresentative experiment.
bND due to lack of cross reacting antibodies.
ND, not done. ***p < 0.001; **p < 0.01; *p < 0.05. 
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performed cell adhesion assays using both SLC and LAP-1
as immobilized ligands. 8-expressing HT1080 cells bound
significantly better to SLC than to LAP-1 at the 1.0 and
2.5 g/ml coating concentrations, whereas mock-trans-
duced HT1080 cells did not bind at all (Fig. 1 f). The rea-
son for the increase in the v8-dependent cell adhesion to
SLC compared with LAP-1 is unclear. However, it is likely
that the presence of the mature TGF-1 peptide in SLC re-
sults in conformational differences between SLC and LAP-
1, which could affect either receptor binding, stability, or
coating efficiency. Thus, we show that SLC is the first and
only known ligand capable of supporting stable v8-medi-
ated adhesion, since VN, the only other known v8
ligand, does not support stable v8-mediated adhesion
(Nishimura et al., 1994).
The integrin v8 mediates activation of SLC
To determine the functional consequence of LAP–v8 inter-
actions, we assessed the ability of v8 to activate the endoge-
nous SLC present in coculture systems. These systems con-
sisted of 8-expressing or mock-transduced cells cocultured
with reporter cell lines (TMLC [Abe et al., 1994] or HepG2-
[SBE]4-Lux [Jonk et al., 1998]) responsive to active TGF-.
We found that the TMLC reporter cell system was a more spe-
cific bioassay system for TGF- activity than the HepG2-
(SBE)4-Lux system and was therefore used for most of these
studies. The TMLC system consists of mink lung epithelial
cells stably transfected with a TGF- responsive fragment of
the plasminogen activator inhibitor-1 promoter driving the lu-
ciferase gene (Abe et al., 1994). TMLC cells are highly respon-
sive to TGF- and produce a very low background of TGF-
activation. TMLC cells can thus be used in coculture with
other cell lines or cell-free fractions to test for the presence of
active TGF- using luminescence as a readout.
In the HT1080, SW480, and H647 cell lines, heterolo-
gous expression of 8 had either no effect or a slight effect
on the cell surface expression of the other integrin  sub-
units known to interact with the RGD motif (Table I). The
only significant differences were a reduction of surface ex-
pression of the 5 subunit in 8-transduced compared with
mock-transduced HT1080 and SW480 cells. It is possible
that these slight reductions in surface expression of v5-
on 8-expressing HT1080 and SW480 cells could poten-
tially reduce the magnitude of the 8 effect on adhesion to
LAP-1 or influence the activation of TGF-. However,
this is unlikely, since the v5 integrin binds very weakly
and does not mediate adhesion to SLC (Fig. 1 f, mock).
Heterologous expression of v8 mediated activation of
TGF- in HT1080, SW480, and MvLu cells as determined
by coculture with either TMLC (Fig. 2, a–d) or HepG2-
(SBE)4-Lux reporter cells (unpublished data). TGF- activa-
tion was specifically mediated by v8, since it was substan-
tially inhibited by the anti-8 antibody, 37E1 (Fig. 2, a–c).
The other RGD binding integrin heterodimers normally
present in SW480, HT1080, and MvLu cells (Table I) did
not mediate significant activation of TGF- because mock-
transduced cells did not activate TGF- (Fig. 2, a–c). How-
ever, H647 cells, which normally express v6 (Table I), ac-
tivated TGF- (note the higher activation in mock H647
cells than in other cell lines in Fig. 2 d). This activation in
mock-transduced H647 cells could be completely inhibited
by antibodies to 6; activation in 8-expressing H647 cells
could be completely inhibited by a combination of 8 and
6 antibodies (unpublished data). These data demonstrate
that when 8 and 6 are coexpressed the resulting TGF-
activation is additive. The TGF- isoform that was prima-
rily responsible for TGF- activation in our system was
TGF-1, since TGF-1 isoform-specific antibodies inhib-
ited 80–90% of the activation in SW480, HT1080, MvLu,
and H647 cells, whereas TGF-2 and TGF-3 isoform-spe-
cific antibodies had minimal effect (unpublished data).
Evidence that the 8-cytoplasmic domain is not 
required for v8-mediated activation of TGF-
The mechanism of integrin v6-mediated activation of
TGF- is likely to depend on the transduction of mechani-
cal forces to induce conformational changes of SLC (Mun-
ger et al., 1999). Thus, v6-mediated activation of TGF-
is critically dependent on specific sequences within the 6
cytoplasmic domain (Munger et al., 1999). However, the
8 cytoplasmic domain has no similarity with the cytoplas-
mic domain of 6 or any other integrin  subunit (Moyle et
al., 1991). We have shown previously that the 8 cytoplas-
mic domain is incapable of linking to the cytoskeleton to
stabilize cell adhesion (Nishimura et al., 1994; Cambier et
al., 2000). Therefore, we sought to determine whether the
8 cytoplasmic domain would influence interactions with
LAP-1. We expressed and tested a series of 8 cytoplasmic
deletion mutants (Fig. 3, a–c) for their ability to mediate ad-
hesion to LAP-1 (Fig. 3 d) and to activate TGF- (Fig. 3, e
and f). The complete (TM) cytoplasmic deletion mutant
was expressed at sixfold lower surface levels than the partial
(759) cytoplasmic deletion mutant or the wild-type (FL)
Figure 2. Cell surface expression of v8 mediates activation of 
TGF-. HT1080 (a), MvLu (b), SW480 (c), and H647 (d) cells either 
8-transduced or mock-transduced were cocultured with TMLC 
reporter cells in the presence or absence of a neutralizing anti-8 
antibody (37E1) or pan–TGF- neutralizing antibody (1D11). Relative 
luciferase units represent arbitrary units minus the TMLC back-
ground. Asterisks indicate increased luciferase activity of untreated 
8-expressing cells compared with antibody-treated or mock 
controls. p  0.001.
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subunit (Fig. 3 c). Low levels of surface expression of the
TM mutant could be due to a decreased ability to associate
with the v subunit, alterations in intracellular transport, or
increased degradation. SW480 cells expressing sixfold lower
surface levels of the TM mutant compared with SW480 cells
expressing the 759 mutant or the FL subunit adhered only
slightly less well to LAP-1 (TM adhesion saturation
reached at 5 compared with 2.5 g/ml coating concentra-
tion for 759 and FL) (Fig. 3 d). Unlike 6-transduced
SW480 cells (Munger et al., 1999), SW480 cells transduced
with full-length or mutant forms of 8 failed to spread ap-
preciably on LAP-1 (unpublished data).
SW480 and HT1080 cells expressing the FL subunit and
the TM and 759 mutants also mediated significant activa-
tion of TGF- compared with mock-transduced cells (Fig.
3, d and e). Concordant with sixfold lower levels of surface
expression, SW480 cells expressing the TM mutant did not
activate TGF-1 as well as cells expressing either 759 mu-
tant or the FL subunit (Fig. 3 b). However, cells expressing
the TM mutant adhered to LAP-1 and activated TGF-
only twofold less than the 759 or FL constructs (Figs. 3,
c–e). This discordance may be due to dependence on the
ligand concentration rather than the receptor number in
these assays (e.g., saturation). Alternatively, it is possible that
the cytoplasmic domain of 8 actually plays a negative regu-
latory role in v8–TGF- interactions. This latter possi-
bility is consistent with the hypothesis that the divergent cy-
toplasmic domain of 8 plays a general inhibitory role
(Cambier et al., 2000). 
Together these findings suggest that the cytoplasmic do-
main of 8 is not required for either adhesion to LAP-1 or
activation of TGF-. Thus, it is likely that the mechanism
of v8-mediated activation of TGF-1 is distinct from the
mechanosignal transduction mechanism described for v6
(Munger et al., 1999).
v8-mediated activation of TGF- 
requires localization to the cell surface 
and metalloprotease activity
The fact that the cytoplasmic domain of 8 is not required
for activation of TGF-1 suggests that v8-mediated acti-
vation of TGF- might be regulated extracellularly either in
the extracellular space or on the cell surface. To test these
possibilities, we first tested the ability of soluble secreted
v8 to activate TGF-. We found no evidence, using a va-
Figure 3. The cytoplasmic domain of 
8 is not required for cell adhesion to 
LAP-1 or activation of TGF-. (a) Con-
struction of 8 subunit cytoplasmic 
truncation mutants. The full-length 8 
(FL) subunit, a partial truncation mutant 
missing the COOH-terminal 11 amino 
acids (759), and a complete truncation 
mutant missing the complete 8 cytoplas-
mic domain (TM) were assembled by PCR 
mutagenesis and subcloned into retroviral 
vectors. (b) Immunoprecipitation analysis 
of surface-labeled SW480 cells, expressing 
FL, 759, TM, or retroviral backbone 
(mock) using an anti-8 monoclonal 
antibody (37E1). The results demonstrate 
the presence and dimerization with the 
v subunit on the cell surface and 
absence of the cytoplasmic domain in 
the TM construct. Biotinylated proteins 
were detected by Western blotting. Note 
that 37E1 is specific to v8 because the 
two immunoprecipitated bands, corre-
sponding to the v subunit or the 8 sub-
unit, were not seen in mock-transduced 
cells. Also, note that the TM construct 
was expressed at lower levels on the cell 
surface compared with 759 and FL. To 
determine the absence of the intracellular 
epitope in TM-expressing cells, cell ly-
sates were immunoprecipitated with 37E1 
and analyzed by Western blotting using a 
polyclonal anti-8 antibody directed against the entire 8 cytoplasmic domain. In b (bottom), note that no signal for 8 is seen in the 8 
immunoprecipitates of the truncation mutant (TM), indicating absence of the 8 cytoplasmic domain. (c) FACS® of cytoplasmic deletion 
mutants (TM and 759) versus the wild type (FL) 8 subunit expressed in SW480 cells. Note the TM mutant is expressed at sixfold lower levels 
than the 759 or FL constructs. Histograms using arbitrary fluorescence units are shown. (d) Adhesion assays of SW480 cells expressing 8 
truncation mutants demonstrate that the cytoplasmic domain of 8 is not required for adhesion to LAP-1. Note that despite lower levels of 
surface expression of the TM construct, all constructs bound well to LAP-1, whereas mock-transduced SW480 cells do not adhere to LAP-1. 
(e-f) Demonstration that the 8 cytoplasmic domain is not required for activation of TGF-. SW480 or HT1080 cells expressing the wild-type 
or truncation mutants were cocultured with TMLC reporter cells in the presence or absence of anti-8 (37E1) or pan anti–TGF- (1D11). 
Relative luciferase units are shown. Single and double asterisks indicate increased luciferase activity of untreated wild-type or mutant 8-expressing 
cells compared with antibody-treated or mock controls (*p  0.01; **p  0.001).
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riety of receptor preparations (supernatant containing se-
creted v8 or lectin- or antibody-purified receptor), that
soluble secreted v8 could activate TGF- (with superna-
tant containing secreted v8 or media control; relative lu-
ciferase units: v8, 7.8 	 0.1; media control, 11.8 	 1.2,
p 
 0.05). This suggests that cell surface localization of
v8 is required for TGF- activation. 
Because proteolytic cleavage is a common mechanism of
regulating cytokine activity, we tested the ability of protease
inhibitors to block v8-mediated activation of TGF-.
GM6001, a member of the hydroxamate class of protease in-
hibitors specific to metalloproteases, but not a control pep-
tide lacking the metal-binding hydroxamate modification
(C1006), significantly blocked v8-mediated TGF- acti-
vation in SW480 (Fig. 4 a) and HT1080 cells (59.0 	
10.0% inhibition using 5 M GM6001; 0.0 	 0.9% using
5 M C1006, p  0.01). This inhibition was specific to
v8 because v6-mediated activation of TGF- was not
inhibited by GM6001 (5 M) in SW480 cells (Fig. 4 a) or
Figure 4. Activation of TGF-1 by v8 is dependent on metallo-
protease activity. (a) GM6001, a hydroxamated metalloprotease 
inhibitor, but not C1006, a nonhydroxamated control peptide, 
inhibits v8-mediated but not v6-mediated activation of TGF- 
in SW480 cells. The asterisk indicates significant inhibition by 
GM6001 of 8-mediated activation compared with the other three 
groups (p  0.01). (b) Only metalloprotease inhibitors inhibit v8-
mediated TGF- activation. Inhibitors to aspartyl (pepstatin A), 
serine (PMSF, CK-23, aprotinin, and leupeptin), or cysteine (leupeptin 
and E64) proteases do not inhibit v8-mediated TGF- activation 
in SW480 cells. 8- and 6-mediated activation was determined by 
neutralization with 37E1 or 10D5 in a or 37E1 in b. The asterisk 
indicates significant inhibition by GM6001 compared with other 
inhibitors (p  0.01).
Figure 5. Active TGF- is liberated into the supernatants of 
v8-expressing cells. (a) Expression of 8 and 6 on the cell 
surface of 8-, 6-, and mock-transduced HT1080 cells using 
monoclonal antibodies specific for the 8 (14E5) or 6 (E7P6) 
integrin subunits. (b) Comparison of 8- and 6-mediated 
activation of TGF- in cocultures with TMLC reporter cells. (c) 
Detection of active TGF- liberated into the supernatant from 
8-expressing but not 6- or mock-transduced HT1080 cells. 
Neutralizing antibodies to TGF- were 1D11, or to 8 or 6 
were 37E1 or 10D5, respectively. Relative luciferase units are 
shown in b and c. The asterisk indicates increased luciferase 
activity from supernatants of untreated 8-expressing cells 
compared with antibody-treated or mock controls (p  0.01).
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HT1080 cells (1.0 	 0.1% inhibition, p 
 0.05). Finally,
other peptide and chemical inhibitors of aspartyl (pepstatin
A), serine (PMSF, CK-23, aprotinin, and leupeptin), or cys-
teine (leupeptin and E64) proteases had no effect on v8-
mediated activation of TGF-1 when used at the maximal
nontoxic doses (Fig. 4 b). Together these data suggest a
novel mechanism of v8-mediated activation of TGF-1
requiring both the cell surface and metalloprotease activity.
Cell surface expression of v8 is associated with 
liberation of active TGF-
All previously described mechanisms of cell-associated pro-
tease-dependent activation of TGF- involve liberation of
active TGF- from SLC, presumably as a result of degrada-
tion of LAP (Lyons et al., 1988, 1990; Abe et al., 1998).
Therefore, we hypothesized that if a cell surface proteolytic
event was involved in v8- but not v6-mediated activa-
tion of TGF- then active TGF- should be released by 8-
but not 6-expressing cells into the cell culture supernatant.
To test this hypothesis, we assayed the supernatants of 8-
expressing, 6-expressing, or mock-transduced HT1080
cells for active TGF-. In HT1080 cells, 8 was expressed
at lower surface levels than 6 (Fig. 5 a). Concordant with
lower expression levels, v8-expressing cells activated less
TGF- than v6-expressing cells in coculture assays (Fig.
5 b). However, when supernatants of 8-expressing, 6-
expressing, and mock-transduced HT1080 cells were tested
only supernatant from 8-expressing cells contained a sig-
nificant amount of active TGF- (Fig. 5 c). The presence of
active TGF- in the cell supernatant of 8-expressing cells
was confirmed by inhibition with anti–TGF- antibodies
(Fig. 5 c). Specificity was demonstrated by inhibition with
anti-8 antibodies and by the relative lack of active TGF-
in the supernatant of mock-transduced HT1080 cells (Fig. 5
c). Supernatant from 6-expressing HT1080 cells also had a
slight but insignificant (p 
 0.05) increase in active TGF-
compared with mock-transduced cells (Fig. 5 c). However,
the presence of active TGF- in the cell supernatant of 6-
expressing cells was not 6 specific, since it was not blocked
by anti-6 antibodies. The presence of active TGF- in the
supernatant of this 6-expressing cell pool is likely due to
random differences in integrin-independent release of active
TGF- by different cell pools, but we cannot exclude that it
is due to an indirect effect of 6 expression in HT1080 cells.
Consistent with the above HT1080 cell data, we also found
that a small but significant amount of TGF-1 was present
in the cell culture supernatant of 8-expressing SW480 cells
(relative luciferase units, 0.92 	 0.23; 37E1, 0.26 	 0.08;
p  0.05). In summary, active TGF- is released into the
supernatant of 8-expressing cells through a 8-dependent
mechanism, suggesting that v8 binds SLC to the cell sur-
face, which facilitates the metalloprotease-dependent release
of active TGF- into the cell supernatant.
Expression of membrane-type 1–MMP is sufficient to 
support v8-mediated activation of TGF-
In the course of screening cell lines for this study, we identi-
fied one squamous lung carcinoma cell line, H1264, that ex-
pressed a low level of v8 on the cell surface but did not
activate TGF-. The inability of H1264 cells to activate
TGF- was not due to low expression levels of v8, since
overexpression of 8 by retroviral transduction did not res-
cue activation (relative luciferase units; 8-transduced, 3.0 	
0.3; 37E1, 2.2 	 0.5; mock-transduced, 3.0 	 0.4;
	37E1, 2.6 	 0.2). Since our current findings suggested
that cell surface expression of a metalloprotease cofactor was
likely involved in v8-mediated activation of TGF-, we
used H1264 cells to facilitate the identification of the spe-
cific metalloprotease(s) involved in v8-mediated activa-
tion of TGF-. Thus, we generated a metalloprotease ex-
pression profile of H1264 cells and compared it to profiles
of the other tumor cell lines used in this study. We concen-
trated on metalloproteases known to localize to the cell sur-
face (MMP-2 [Brooks et al., 1996], MMP-7 [Yu and
Woessner, 2000], MMP-9 [Yu and Stamenkovic, 1999],
Figure 6. MT1-MMP is deficient and can be reconstituted in the 
human lung carcinoma cell line H1264. (a) RT-PCR screening of 
tumor cell lines with MT1-MMP–specific primers demonstrates an 
absence of MT1-MMP in H1264 cells. A control amplification 
performed in parallel using -actin primers is shown. (b) Western 
blotting confirms the expression of MT1-MMP and MT1-MMP in 
transduced H1264 cells. Cell lysate from MT1-MMP or mock-
transduced H1264 cells (40 g protein) or cell supernatant from 
MT1-MMP–transduced H1264 cells was resolved by 10% SDS 
page, and proteins were detected by Western blotting using an 
anti–MT1-MMP monoclonal antibody. The expected migration of 
the full-length form of MT1-MMP is 63 kD. Note that the secreted 
form (MT1-MMP) migrates faster (54 kD), and the mock-infected 
cells express no MT1-MMP. (c) MT1-MMP, MT1-MMP, or mock-
transduced 8-overexpressing H1264 cells were plated onto 
96-well dishes in serum-free medium containing recombinant 
pro–MMP-2. After an overnight incubation at 37C in 5% CO2, the 
supernatants were subjected to gelatin zymography (1 mg gelatin/ml, 
10% SDS-PAGE). Pro-MMP2 migrates at 66 kD, and the fully activated 
form migrates at 59 kD. Note that only MT1-MMP–transduced 
H1264 cells activate MMP-2. MMP activity is shown as lucent 
bands against a dark Coomassie-stained background.
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membrane-type 1 [MT1]-MMP [Sato et al., 1994], and a
disintegrin and a metalloprotease domain [ADAM]-9, -10,
and -17 [Primakoff and Myles, 2000]). Using reverse tran-
scriptase (RT)–PCR (Fig. 6 a) and gelatin zymography (un-
published data), we found that the only metalloprotease that
was deficient in H1264 cells, relative to the other tumor cell
lines used in this study, was MT1-MMP. To reconstitute
MT1-MMP expression in H1264 cells, we introduced either
a full-length (MT1-MMP) or a transmembrane-deleted se-
creted form of MT1-MMP (MT1-MMP). Expression or
lack of expression of MT1-MMP in transduced or mock-
transduced H1264 cells was verified by immunoblotting
(Fig. 6 b). Immunoblots revealed an appropriate 63-kD
band in cell lysates from MT1-MMP–transduced H1264
cells (Fig. 6 b) and a 54-kD band from the supernatant of
MT1-MMP–transduced cells (Fig. 6 b). The absence of
any bands in mock-transduced cells confirmed the absence
of MT1-MMP in the parental H1264 cell line (Fig. 6 b).
Reconstituted MT1-MMP was active in H1264 cells as de-
termined by the ability of MT1-MMP–transduced but not
MT1-MMP–transduced or mock-transduced H1264 cells
to cleave pro–MMP-2 to its fully active (59 kD) form (Fig.
6 c). Secreted MT1-MMP possessed gelatinolytic activity
as determined by zymography (unpublished data).
H1264 cells transduced with either MT1-MMP, MT1-
MMP, or vector alone (mock) underwent a second trans-
duction to overexpress similar levels of v8 as determined
by flow cytometry using the anti-8 antibody, 14E5 (Fig.
7 a), or SN1 (unpublished data). For 8-overexpressing
H1264 cells, only those transduced with MT1-MMP and
not MT1-MMP or vector alone (mock) were able to sup-
port activation of TGF- (Fig. 7 b). H1264 cells transduced
with MT1-MMP alone supported a low level of v8-medi-
ated activation of TGF- (relative luciferase units; no mono-
clonal antibody, 2.7 	 0.2; 37E1, 1.3 	 0.0; 1D11,
0.3 	 0.01), which is consistent with their lower levels of
surface expression of v8. A significant portion of the
TGF- activation was specific to 8 and to metalloproteases
because it was inhibited by anti-8 antibodies (37E1),
TIMP-2, and GM6001. 37E1, TIMP-2, and GM6001 were
less efficient than the pan–TGF- antibody (1D11) in in-
hibiting TGF- activity. TIMP-2, a relatively specific inhib-
itor of MT1-MMP (Brew et al., 2000), inhibited TGF- ac-
tivation equally well as 37E1 (Fig. 7 c). The inability to
completely block the 8-, MT1-MMP–dependent activa-
tion of TGF- with anti-8 antibodies and MMP inhibitors
is likely due to a combination of factors: antibody efficacy,
steric hindrance on the cell surface (Atkinson et al., 2001)
and/or the high heterologous expression levels of both 8
and MT1-MMP.
v8 and MT1-MMP colocalize in substrate contacts
Our cell biologic and biochemical data indicated that v8 and
MT1-MMP were likely to associate on the cell surface. Thus,
we hypothesized that upon ligation with LAP-1, v8 and
MT1-MMP would cocluster in membrane complexes. To ad-
dress this hypothesis, we expressed an MT1-MMP fusion con-
struct with a COOH-terminal green fluorescent protein
(GFP) tag. The purpose of the GFP tag was to obviate the use
of available commercial anti–MT1-MMP antibodies, which we
Figure 7. v8 mediates activation of TGF- in 8-overexpressing 
H1264 cells reconstituted with MT1-MMP activity. (a) Flow 
cytometry of 8-transduced MT1-MMP, MT1-MMP, or mock-
transduced H1264 cells demonstrates equivalent levels of surface 
expression of 8 using an anti-8 antibody (14E5). Histograms 
using arbitrary units are shown. (b) 8-overexpressing H1264 
cells transduced with either MT1-MMP, MT1-MMP, or the retro-
viral vector alone (mock) (1.6  104) were cocultured with TMLC 
(1.6  104) reporter cells in the presence or absence of inhibitors: 
anti-8 (37E1), control peptide (C1006), GM6001, or the pan–TGF-1 
antibody (1D11). Asterisks indicate significantly different than 
untreated MT1-MMP–expressing cells. (c) The endogenous inhibitor 
TIMP-2 but not TIMP-1 inhibits v8-mediated activation of TGF- 
in H1264s cells. 8-overexpressing, MT1-MMP–expressing 
H1264s cells were cocultured with TMLC in the presence or 
absence of TIMP-1 (1 g/ml), TIMP-2 (1 g/ml), GM6001 (5 M), 
anti-8 (37E1), or pan-TGF-1 (1D11). Relative luciferase units 
are shown (light units of cocultured cells in the presence or 
absence of inhibitors minus light units of TMLC cells alone) in b 
and c. Negative luciferase values were occasionally observed due 
to a small background of TGF- activation by the TMLC cells. 
Single and double asterisks indicate treated cells compared with 
untreated cells (*p  0.01; **p  0.001).
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found unsuitable for immunocytochemistry (unpublished data).
MT1-MMP–GFP was expressed on the cell surface of 8-
expressing HT1080 cells as determined by surface labeling fol-
lowed by immunoprecipitation with anti-GFP antibodies.
Anti-GFP antibodies immunoprecipitated two bands from
MT1-MMP–GFP–expressing cells, the upper band represent-
ing the catalytically active form of MT1-MMP–GFP and the
lower band the degraded form, lacking the catalytic domain
(Overall et al., 2000) (Fig. 8 a, top). Furthermore, MT1-
MMP–GFP was found to be functionally active as determined
by potentiation of the zymographic conversion of pro-MMP2
to active MMP2 (Fig. 8 a, bottom).
We determined using confocal microscopy that 8 and
MT1-MMP–GFP exactly colocalized in discrete clusters in the
plane of an LAP-1 substrate using anti-8 and GFP antibod-
ies (Fig. 8, b–d). The localization of 8 to these substrate con-
tacts was not due to “bleed-over” of the MT1-MMP–GFP sig-
nal, since the GFP signal was not intense enough to visualize
without staining with an anti-GFP antibody and 8 localiza-
tion was seen in 8-expressing HT1080 cells not transduced
with MT1-MMP–GFP (Fig. 8, e–g). As expected, antibodies
against the v subunit colocalized with antibodies against the
8 subunit in these contacts when cells were plated on LAP-1
(unpublished data). Localization of 8 was not dependent
on MT1-MMP expression, since 8 was found in substrate
contacts in MT1-MMP–deficient 8-expressing H1264 cells
plated on an LAP-1 substrate (unpublished data). Localization
of MT1-MMP–GFP to substrate contacts was not due to non-
specific accumulation of GFP or to a staining artifact, since no
substrate contacts were found with anti-GFP antibodies in
GFP-transduced non-8–expressing HT1080 cells plated on
LAP-1 (Fig. 8, h–j). Localization of MT1-MMP to LAP-1
substrate contacts was dependent on 8 expression, since no
contacts were found in non-8–expressing, MT1-MMP–
GFP–expressing HT1080 cells (unpublished data). Finally, the
colocalization of 8 and MT1-MMP to substrate contacts re-
Figure 8. v8 and MT1-MMP colocalize in substrate contacts. 
(a, top) Immunoprecipitation of MT1-MMP–GFP from 125I cell 
surface-labeled MT1-MMP–GFP–expressing HT1080 cells. The 
catalytically active 90-kD MT1-MMP–GFP fusion protein (asterisk) 
was immunoprecipitated with anti-GFP antibodies from MT1-MMP–
GFP–expressing HT1080 8 cells but not mock-transduced HT1080 
8 cells. The 70-kD MT1-MMP–GFP band represents a catalytically 
inactive degradation product. (a, bottom) Gelatin zymography of 
supernatants from MT1-MMP–GFP–transduced or mock-transduced 
HT1080 8 cells. The migration of Pro (Pro) and active (Act.) 
forms of MMP-2 are shown. (b–m) Confocal images of immunofluores-
cence microscopy. 8-expressing, MT1-MMP–GFP–expressing 
HT1080 cells (b–d and k–m); 8-expressing HT1080 cells (e–g); 
GFP-expressing HT1080 cells (h–j). Cells were allowed to attach 4 h 
to LAP-1 (10 g/ml coating concentration)-coated slides. After 
fixation and permeabilization, colocalization of 8 and GFP was 
determined using polyclonal anti-8 and monoclonal anti-GFP anti-
bodies. Pseudocolored confocal images of 8 (red) and GFP (green) 
staining taken in the plane of the substrate are shown. Bar, 7.5 M.
Figure 9. Cell surface-associated MT1-MMP cleaves and inactivates 
LAP-1. (a) LAP-1 is cleaved by incubation with 8-overexpressing 
MT1-MMP but not MT1-MMP or mock-transduced H1264 cells. 
LAP-1 (10 g/ml) was incubated overnight with either no cells 
(lane 1), mock-transduced 8-overexpressing H1264 cells (lane 2), 
MT1-MMP transduced, 8-overexpressing H1264 cells (lane 3), 
MT1-MMP transduced, 8-overexpressing H1264 cells (lane 4), 
500 g/ml of control peptide (C1006; lane 5), or 500 g/ml 
hydroxymate inhibitor GM6001 (lane 6). 20 ng of the input LAP-1 
was resolved by 12.5% SDS-PAGE under reducing conditions. After 
immunoblotting with an anti-LAP antibody, the migration of the 
cleavage products calibrated to molecular weight standards (GIBCO 
BRL) is shown. Note that only LAP-1 incubated in the presence of 
MT1-MMP is cleaved and that this cleavage is blocked by GM6001. 
(b) The TGF-1 peptide GRRGDLATIH selectively inhibits v8–
LAP-1 function. Adhesion assay of 8-overexpressing, MT1-MMP 
expressing H1264 cells (4  104) to LAP-1, VN, or fibronectin (FN) 
(10 g/ml coating concentrations) in the presence or absence of 50 
g/ml of GRRGDLATIH. (c) LAP-1 cleavage by MT1-MMP–
transduced, 8-overexpressing H1264 cells is inhibited by GRRGD-
LATIH but not GRRGELATIH peptide (10 g/ml). The degradation 
assay was performed and analyzed by immunoblotting as in a. 
No-cell control (lane 1); no-inhibitor control (lane 2); control GR-
RGELATIH peptide (lane 3); GRRGDLATIH peptide (lane 4). (d) 
LAP-1 is inactivated by 8-overexpressing, MT1-MMP-expressing 
H1264 cells. LAP-1 (5 g) incubated overnight with 8-overexpressing, 
MT1-MMP-expressing or 8-overexpressing, mock-transduced 
H1264 cells was added to TMLC reporter cells in the presence of 
recombinant TGF-1. As a control (white bars) TMLC reporter cells 
were incubated with only recombinant TGF- and no LAP-1. Relative 
luciferase units are shown. The asterisk indicates LAP-1 incubated 
with mock control cells is not cleaved and decreases TGF- activity 
compared with other groups (p  0.05).
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quired ligand engagement, since no such contacts were found
when 8-, MT1-MMP–GFP expressing HT1080 cells were
plated on an irrelevant ligand, collagen I (Fig. 8, k–m). In con-
clusion, ligation of v8 with LAP-1 results in the specific
colocalization of v8 and MT1-MMP in substrate contacts,
suggesting a biologically relevant and close physical interaction.
Overexpression of MT1-MMP is sufficient to cleave 
and inactivate LAP-1
To determine if proteolysis of LAP-1 could be a mecha-
nism of v8-mediated activation of TGF-, we incubated
recombinant LAP-1 with 8-overexpressing H1264 cells
transduced with either MT1-MMP, MT1-MMP, or vec-
tor alone. After incubation of LAP-1 with mock or
MT1-MMP–expressing H1264 cells, LAP-1 remained
intact (32 kD). In contrast, we found that almost all of the
LAP-1 incubated with MT1-MMP–expressing H1264
cells was smaller (26–28 kD) than intact LAP-1, suggesting
proteolytic cleavage (Fig. 9 a, lane 4). LAP-1 cleavage was
dependent on the metalloprotease activity of MT1-MMP,
since the metalloprotease inhibitor GM6001 but not a con-
trol peptide C1006 completely blocked cleavage (Fig. 9 a,
lanes 5 and 6). To determine if LAP-1 cleavage was also
dependent on v8, we developed a peptide based on the
human LAP-1 sequence, which was a relatively specific
inhibitor of v8–LAP-1 interactions. In the H1264
system, the GRRGDLATIH peptide completely blocked
v8–LAP-1 interactions while having a minimal effect
on the binding of other RGD-dependent integrins to VN or
fibronectin (Fig. 9 b). Using these peptide inhibitors, we de-
termined that LAP-1 cleavage was also dependent on
v8, since GRRGDLATIH but not the RGE mutant pep-
tide inhibited LAP-1 cleavage (Fig. 9 c). Thus, in the
H1264 cell system, v8 and MT1-MMP together are re-
quired for LAP-1 cleavage. Finally, v8-, MT1-MMP–
dependent cleavage of LAP-1 is functionally relevant, since
LAP-1, after cleavage, loses the ability to inhibit the func-
tion of the recombinant mature TGF-1 peptide (Fig. 9 d).
TGF- activated by the integrin v8 in human lung 
cancer xenografts results in growth inhibition and 
tumor fibrosis
To test the physiologic relevance of v8-mediated activa-
tion of TGF-1, we employed the H647 lung carcinoma
cell system, which we have described recently (Cambier et
al., 2000). We employed this system because 8 is expressed
mainly by the basal cells of the human airway (Cambier et
al., 2000), a cell type that is difficult to isolate in sufficient
numbers for our studies and difficult to maintain in culture
(Hicks et al., 1997). Because we have demonstrated recently
that the growth of 8-expressing H647 cells was inhibited
relative to mock-transduced H647 cells (Cambier et al.,
2000), we asked if TGF- might be a mediator of that
growth inhibition. To address this question, we determined
BrdU incorporation as a measure of DNA synthesis in 8-
expressing and in mock-transduced H647 cells. We deter-
mined that the growth of 8-expressing H647 cells was po-
tently inhibited relative to mock-transduced control cells as
reflected by reduced BrdU incorporation (Fig. 10 a). In ad-
dition, since TGF- characteristically induces a cell cycle ar-
rest late in G1 (Laiho et al., 1990) we studied the cell cycle
defect in H647 cells. Nonsynchronized 8-expressing H647
cells displayed a partial G1 arrest when compared with
mock-transduced H647 cells (G1 fraction of 8-expressing
H647 cells, 62% 	 3%; mock-transduced H647 cells, 47 	
3%, p  0.05). Furthermore, we found that this 8-depen-
dent growth inhibition was also TGF-–dependent because
it could be reversed by TGF- antibodies (Fig. 10 a) or by
recombinant LAP-1 (for 8-expressing H647 cells without
LAP-1, G1 fraction, 61%; with LAP-1, 51%, in a repre-
sentative experiment). Thus, TGF- is a mediator of 8-
induced growth inhibition in vitro.
Figure 10. The activation of TGF- by v8 is associated both 
with growth inhibition and with fibrogenesis in lung cancer tumor 
xenografts. (a) DNA synthesis is inhibited in v8-expressing H647 
cells, and the inhibition is reversed by TGF- blocking antibodies 
(1D11). The asterisk indicates increased BrdU incorporation of anti-
body-treated 8-expressing cells compared with untreated 8-
expressing cell (p  0.05). (b) Histologic analysis of tumors grown 
in nude mice derived from either 8-expressing or mock-transduced 
H647 cells. Trichrome-stained sections highlighting dense collagen 
(green area between arrows) between islands of tumor cells (t) are 
shown. Bar, 75 m. (c) Determination of active and SLC in 8-
expressing and mock-transduced lung tumor xenografts. Relative 
luciferase units are shown. The asterisk indicates increased active 
TGF- from 8-expressing tumors compared with mock-transduced 
tumors (*p  0.01).
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To address if v8 also mediated TGF- activation in
vivo, we used 8-expressing or mock-transduced H647 cells,
which are tumorigenic in nude mice (Cambier et al., 2000).
Using this system, we have found 8-expressing tumors to
be significantly smaller than their mock-transduced counter-
parts (Cambier et al., 2000). Because fibrosis is one of the
histologic hallmarks of increased TGF- activity (Border
and Noble, 1994), we examined 8-expressing tumors his-
tologically for evidence of fibrosis. We found that 8-
expressing tumors were not only smaller but were more fi-
brotic than tumors derived from mock-transduced cells (Fig.
10 b). To determine if the reduction in tumor size and the
increase in stromal fibrosis were associated with increased ac-
tive TGF-, we used the TMLC reporter cells to determine
the active and SLC activities associated with 8-expressing
and mock-transduced H647 tumor xenografts. Using this
bioassay, there was a significant increase in the amount of
active TGF- present in the aqueous fraction of 8-express-
ing tumors relative to control tumors (Fig. 10 c). In con-
trast, the latent component of TGF- did not differ between
tumors derived from 8-expressing or mock-transduced
H647 cells (Fig. 10 c). Thus, in vivo v8 can liberate phys-
iologic levels of TGF- activity. Moreover, these data sug-
gest that in normal tissues v8-mediated activation of
TGF- must be more tightly regulated than in the tumor
xenograft model, since fibrosis is only associated with patho-
logic states (Blobe et al., 2000).
Discussion
We have found previously that the integrin v8 inhibits
epithelial cell growth (Cambier et al., 2000). Furthermore,
v8 is expressed in either quiescent cells or cells with a low
rate of turnover (Nishimura et al., 1998; Cambier et al.,
2000) and is lost in the process of neoplastic transformation
(Cambier et al., 2000). These findings led us to hypothesize
that 8 plays a role in the homeostatic control of normal tis-
sues. In support of this hypothesis, we now demonstrate that
the integrin v8 mediates growth inhibition through a
novel mechanism of activation of TGF-1, a cytokine with
a central role in homeostatic cellular processes (Blobe et al.,
2000).
Two molecular mechanisms have been proposed that may
lead to the activation of TGF-1: conformational change
leading to activation of the SLC complex (Crawford et al.,
1998; Munger et al., 1999) or proteolysis of LAP-1 leading
to the release of active TGF-1 (Munger et al., 1997; Yu
and Stamenkovic, 2000). Our data demonstrate that a
mechanism of conformational change leading to activation
of TGF-, as proposed for the v6 integrin (Munger et al.,
1999) or TSP-1 (Crawford et al., 1998), is not responsible
for v8-mediated activation of TGF-1. Specifically,
v8-mediated activation of SLC does not require the 8
cytoplasmic domain in contrast to the mechanism of v6-
mediated activation of TGF-, which requires the 6-cyto-
plasmic domain (Munger et al., 1999). Furthermore, v8
is unlikely to bind directly or indirectly to LAP-1 through
a TSP-1–dependent mechanism because v8 lacks the de-
fined TSP-1 binding site for LAP-1 (Crawford et al.,
1998) and v8 does not bind to TSP-1 (unpublished
data). Moreover, unlike secreted TSP-1 (Crawford et al.,
1998) secreted v8 cannot activate TGF-1. Thus, the
mechanism by which v8 activates TGF-1 is not depen-
dent on conformational changes, resulting from “inside-out”
signal transduction as mediated by the 6 cytoplasmic do-
main (Munger et al., 1999) or direct physical interaction as
mediated by TSP-1(Crawford et al., 1998).
Our findings support a biologically relevant mechanism
whereby SLC binds with high affinity to v8 on the cell
surface, which results in the metalloprotease-dependent re-
lease of active TGF-. Evidence to support this mechanism
follows: (a) secreted v8 binds to LAP-1 with a high af-
finity with a dissociation constant similar to other TGF-
receptors (Tucker et al., 1984); (b) both synthetic and en-
dogenous MMP inhibitors block v8-mediated activation
of TGF-1; (c) reconstitution of MT1-MMP into the
H1264 MT1-MMP–deficient cell line rescues v8-medi-
ated TGF- activation; (d) v8 and MT1-MMP specifi-
cally colocalize in LAP-1 substrate contacts; (e) consistent
with a proteolytic event, active TGF- is liberated by an
v8-dependent mechanism into the supernatants of tu-
mor cell lines and into the aqueous phase of lung cancer
xenografts; (f) the proteolytic substrate of v8-, MT1-
MMP–dependent activation of TGF-1 is likely to be
LAP-1, since 8-overexpressing, MT1-MMP–expressing
H1264 cells cleave and inactivate LAP-1, whereas 8-over-
expressing, MT1-MMP–deficient H1264 cells do not; (g)
cleavage of LAP-1 requires the concomitant activity of
both 8 and MT1-MMP, since 8-specific RGD inhibitors
and metalloprotease inhibitors both block cleavage. Prece-
dent for such a proteolytic mechanism is that plasmin (Ly-
ons et al., 1990) and MMP-9 (Yu and Stamenkovic, 2000)
have each been shown to activate TGF-1 and TGF-2, re-
spectively, by cleavage of LAP.
It is also possible that MT1-MMP acts indirectly by pro-
teolytically modifying the activity of v8 as suggested re-
cently for the MT1-MMP–dependent modification of the
integrin v3 (Deryugina et al., 2000). However, this is un-
likely because of the following: (a) cell lines expressing v8
attach to LAP-1 equally well whether or not they express
MT1-MMP (unpublished data), suggesting that coexpres-
sion of MT1-MMP does not modify the activity of v8;
(b) flow cytometry of H1264 cells overexpressing both 8
and MT1-MMP using two different anti-8 monoclonal
antibodies shows no alteration in surface expression of
v8, indicating that antibody epitopes are preserved along
with adhesive capability; (c) immunoprecipitations or West-
ern blots of cells coexpressing v8 and MT1-MMP, using
polyclonal antibodies against the cytoplasmic domain of 8,
show no electrophoretic shift or proteolytic degradation
products. Therefore, we have no evidence of modification of
v8 by MT1-MMP.
How does MT1-MMP interact with the v8–TGF-1
complex? Our data suggest that upon ligation of v8 with
SLC, v8 and MT1-MMP become closely associated to
form a complex on the cell surface. The cell surface appears
to be required for productive interactions, since the secreted
forms of v8 and MT1-MMP do not mediate activation
of TGF-. Evidence for a physical association on the cell
surface is that v8 and MT1-MMP colocalize in substrate
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contacts specifically on LAP-1. The nature of the MT1-
MMP–8 interaction awaits elucidation by coimmunopre-
cipitation and domain interaction studies. Because the local-
ization of MT1-MMP in LAP-1 substrate contacts is
dependent on the presence of 8, it is likely that v8–SLC
interactions are required to initiate the recruitment of MT1-
MMP. The dynamic recruitment of MT1-MMP to v8–
TGF- complexes could provide a basis for the homeostatic
regulation of TGF- activity in cellular microenvironments.
Although reconstitution of wild-type MT1-MMP is suffi-
cient to support v8-mediated activation, other metallo-
proteases could potentially be involved. For instance, MT1-
MMP binds to and is potently inhibited by TIMP-2 (Brew
et al., 2000), but MT1-MMP–TIMP-2 complexes also serve
as a cell surface receptor for MMP-2, and the function of
this complex is activation of MMP-2 (Strongin et al., 1995).
As such, it is not inconceivable that MMP-2 could also be
involved in v8-mediated activation of TGF-. However,
in H1264s cells MMP-2 is unlikely to be involved, since
TIMP-1, a potent inhibitor of MMP-2 and weak inhibitor
of MT1-MMP (Brew et al., 2000), has no effect on v8-
mediated activation of TGF-. In contrast, 8-mediated
TGF- activation is inhibited by TIMP-2, suggesting that
MT1-MMP may alone be sufficient to support 8-mediated
activation of TGF-. Although formally we cannot exclude
additional roles for other MMPs or related metalloproteases
such as ADAMs or ADAMTS, family members in v8
mediated activation of TGF- in other systems or cell types.
The 8 subunit appears to be the only integrin subunit
capable of coordinating metalloprotease activity with SLC
bound to the cell surface because the other LAP-1 binding
integrins are either incapable of activating TGF- (Munger
et al., 1998) or, in the case of v6, activating TGF- via a
metalloprotease-independent pathway (Munger et al.,
1999). Furthermore, v8-mediated TGF- activation is
solely dependent on metalloproteases and not other pro-
teases because inhibitors of aspartyl, serine, and cysteine pro-
teases do not inhibit activation. Thus, v8-mediated acti-
vation of TGF-1 is not dependent on other proteases that
have been implicated in SLC activation, including plasmin
(Lyons et al., 1990), calpain (Abe et al., 1998), and cathep-
sin (Lyons et al., 1988).
Integrins (Brooks et al., 1996) and other cell surface mole-
cules (Yu and Stamenkovic, 1999) have also been shown to
localize MMP activity to the cell surface. For instance, the
integrin v3 has been shown to form an SDS stable cell
surface complex with MMP-2 (Brooks et al., 1996) and to
colocalize with MT1-MMP (Deryugina et al., 2001),
whereas CD44 has been shown to mediate localization of
MMP-9 (Yu and Stamenkovic, 2000) to the cell surface.
However, v3 and CD44 are unlikely to be required for
v8-mediated activation of TGF- because v3 is not
expressed in multiple cell lines that support v8-mediated
activation of TGF- (Table I) and because anti-CD44 anti-
bodies do not inhibit v8-mediated activation of TGF-
(unpublished data).
The selective MMP dependence of v8- but not v6-
mediated activation of TGF-1 clearly demonstrates that
the mechanisms of v8- and v6-mediated activation of
TGF-1 are different. A structural basis for these different
mechanisms may be the striking difference in the predicted
secondary structure of the extracellular domains of the 8
and 6 subunits (Moyle et al., 1991). Different integrin-
mediated mechanisms of TGF- activation may have evolved
to support distinct biologic functions. For instance, in the
airway epithelium, a site where 8 is normally expressed
(Cambier et al., 2000), a mechanism to support a low and
persistent level of activation of TGF-1 is necessary for ho-
meostasis (Crawford et al., 1998). We speculate that v8
could sequester SLC to the cell surface where, in response to
an environmental cue, changes in the local balance of MMP/
TIMP activity could lead to v8-dependent liberation of
active TGF-1. Thus, v8-mediated activation of TGF-
1 might liberate the low levels of active TGF-1 sufficient
to promote local paracrine effects but insufficient for unde-
sirable local and systemic fibrogenic effects of TGF-1 (Bor-
der and Noble, 1994). Conversely, if v6 were to liberate
TGF- by an MMP-dependent mechanism undesirable
pathologic levels of TGF- might be released locally and
into the systemic circulation because after injury expression
of v6 (Breuss et al., 1993; Pilewski et al., 1997) and
MMPs (Holgate et al., 1999) are both strongly and rapidly
induced.
In summary, abundant evidence implicates the cytokine
TGF-1, integrins, and MMPs as important mediators of
homeostatic cell behaviors. This article provides the first evi-
dence of the coordination of activity of members of these
three major multigene families in the maintenance of ho-
meostasis.
Materials and methods
Cell lines and reagents
Cell lines used include SW480, HT1080, H1264, HepG2, 293, SP2/0
(American Type Culture Collection), NCI H647 (Tsai et al., 1993), the am-
photrophic retroviral packaging line Phoenix (Kinsella and Nolan, 1996),
MvLu mink lung epithelial cells stably transfected with a plasminogen acti-
vator inhibitor promoter-1–luciferase construct (TMLC cells [Abe et al.,
1994]), and High-Five (Invitrogen). Early passage parental H1264 cells de-
ficient in MT1-MMP were subcloned by limiting dilution to achieve a phe-
notypically stable MT1-MMP–negative subclone (H1264s). LAP-1 was
produced using recombinant baculovirus-expressing wild-type simian
LAP-1 and mutant (RGE) LAP-1 as described (Munger et al., 1998). LAP-
1–Sepharose was prepared by cross-linking 2 mg of protein A–tagged
LAP-1 to 1 ml of IgG Sepharose using 20 mM dimethylpimelimidate; VN-
Sepharose was prepared as described (Nishimura et al., 1994). Human re-
combinant active TGF-1, SLC, monoclonal anti-TGF- (1D11) and affin-
ity purified anti–TGF-1, -2, and -3 were purchased from R&D Systems.
The following proteases and protease inhibitors were also purchased:
GM6001 (Galardy et al., 1994) and control C1006 (AMS Scientific, Inc.),
PMSF, E-64 (Sigma-Aldrich), CK-23 (Enzyme Systems Products), leupeptin,
aprotinin, and pepstatin A (Boehringer-Mannheim), and human recombi-
nant TIMP-1, TIMP-2, and Pro-MMP-2 (Chemicon).
The following previously characterized antibodies were used: anti-8,
SN1 (Nishimura et al., 1994), anti-6, 10D5 (Munger et al., 1999), E7P6
(Weinacker et al., 1994), polyclonal affinity purified rabbit anti-8 (Nish-
imura et al., 1994), anti–LAP-1 (VB3A9) (Munger et al., 1998), and anti–
CD-44 (Picker et al., 1989) (Developmental Studies Hybridoma Bank). The
following commercial antibodies and conjugates used were: anti-5
(P5D10; Chemicon), anti-1 (P5D2; Chemicon), pan-anti–TGF- (1D11;
R&D Systems), mouse or rabbit anti–MT1-MMP (Calbiochem and Chemi-
con), mouse anti-BrdU (Dako), phycoerythrin goat anti–mouse, rhodamine
donkey anti–rabbit (Chemicon), phycoerythrin goat anti–mouse, rhodamine
goat anti–mouse (Jackson ImmunoResearch Laboratories), HRP-conjugated
sheep anti–mouse (Amersham Pharmacia Biotech), HRP anti–rat (Cappel),
HRP–protein A (Amersham Pharmacia Biotech). VN was prepared from out-
dated fresh frozen human plasma (Yatohgo et al., 1988). Collagen type 1
was prepared from rat tails (Montesano et al., 1983). Peptides (GRGDSNK
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and GRGESNK) were purchased (BioMol) or were commercially synthesized
(GRRGDLATIH and GRRGELATIH) (BioSyn). The following antibiotics were
used: puromycin, chloroquine (Sigma-Aldrich), geneticin (G418; GIBCO
BRL), hygromycin (Calbiochem), and Fungizone, penicillin, and streptomy-
cin (University of California at San Francisco cell culture facility).
Retroviral vectors, constructs, and RT-PCR
Retroviral vectors used were pLXSN (CLONTECH Laboratories, Inc.), pBabe
Puro (a gift from Dr. Hartmund Land, Imperial Cancer Research Fund,
London, UK) (Morgenstern and Land, 1990), pBabe8Puro, pLXSN8Neo
(Cambier et al., 2000), and pBabe6Puro. The 6 cDNA was subcloned
from 6-Peak10 (a gift from R. Pytela, University of California at San Fran-
cisco) into pBabe Puro. Plasmids were purified using the QIAGEN plasmid
purification system. 8 truncation mutants were constructed using a PCR
strategy introducing COOH-terminal truncations (amino acids 712 and 758
of the 8 ORF [Moyle et al., 1991]), which replace the cytoplasmic domain
of full-length 8 cDNA in pcDNAIneo (Invitrogen). The mutant constructs
were subcloned into pLXSN (CLONTECH Laboratories, Inc.). Truncated 8
with a COOH-terminal AP tag (AP-v8) was produced by in-frame blunt
end ligation of the BspE1-Xho1 placental fragment from AP tag (Flanagan
and Leder, 1990) into a chimeric pcDNAI8/3neo construct (Nishimura et
al., 1994). Full length MT1-MMP or transmembrane and cytoplasmic do-
main deleted MT1-MMP (MT1-MMP) (a gift from Stephen Weiss, Univer-
sity of Michigan, Ann Arbor, MI) were subcloned into pBabe Puro or
pLXSN. A construct creating a MT1-MMP–GFP fusion protein (MT1-MMP–
pLEGFP) was created by destroying the stop codon of MT1-MMP in PCR3.1
by PCR mutagenesis to create a unique HpaI site. The HindIII, HpaI MT1-
MMP fragment was then subcloned in-frame into pLEGFP (CLONTECH
Laboratories, Inc.) between a HindIII and Klenow-treated BamHI site. Se-
quencing in both orientations was performed to verify the fidelity of each
construct. Transfection of packaging cells and retroviral transduction was
performed as described (Kinsella and Nolan, 1996). Pools of 8-expressing
cells were either used within 72 h for short term experiments or were sorted
for uniform expression of 8 and propagated on type I collagen-coated
plates for long term experiments (Cambier et al., 2000). The (SBE)4-Lux re-
porter, which contains 4 CAGACA repeats of the SMAD binding element of
the JunB promoter (Jonk et al., 1998), was a gift of Peter ten Dijke (Ludwig
Institute for Cancer Research, Uppsala, Sweden). Total cellular RNA was
harvested using a commercial kit (QIAGEN), and RT-PCR was performed as
described (Nishimura et al., 1994). Primers, based on published sequences
(Giambernardi et al., 1998; McCulloch et al., 2000) to MMP-2, -7, and -9,
MT1-MMP, ADAMS-9, -10 and -17, and -actin were purchased (Operon
Technologies). Annealing temperatures were based on published reports
(Giambernardi et al., 1998; McCulloch et al., 2000).
Affinity chromatography, ligand binding, and adhesion assays
125I surface labeling and affinity chromatography was performed as de-
scribed (Nishimura et al., 1994). Plasmids containing inserts for AP-tagged
truncated secreted 8 and truncated secreted v in pCDM8 (Nishimura et
al., 1994) were stably expressed in 293 cells and characterized by immu-
noprecipitation (Nishimura et al., 1994). Serum-free supernatant contain-
ing AP-tagged v8 (v8-AP) was applied to 96-well plates precoated
with LAP-1 (wild-type and mutant), VN, or BSA for 1 h at 37C in the
presence and absence of monoclonal antibodies. Bound receptor was de-
tected colorimetrically with pNPP (Sigma-Aldrich) at A405. For affinity
measurements, serum-free supernatant containing secreted AP-v8 was
concentrated 40-fold (Vivaspin 100; Vivascience) and was applied to 10
l of LAP-1–Sepharose, VN-Sepharose, or IgG-Sepharose (Amersham
Pharmacia Biotech) in the presence or absence of 1 mg/ml RGD peptide
and incubated overnight at 4C. The receptor concentration was de-
termined against a standard curve generated using placental AP (Applied
Biosystems). The samples were washed three times in wash buffer
(Tris, 50 mM, pH 7.4, NaCl, 150 mM, CaCl2, 1 mM). Luminescence was
determined using disodium 3-(4-methoxyspiro(1,2-dioxetane-3,2’-[(5-
chloro)tricyclo(3,3.1.13.7)decan]-4-yl) phenyl phosphate (CSPD) as a
substrate (Tropix; Applied Biosystems) according to the manufacturer’s in-
structions. Specific binding was defined as binding that remained after in-
cubation with a 200-fold excess of RGD peptide. Binding curves were
generated using nonlinear regression (Prism; GraphPad Software) from
three independent experiments. Adhesion assays were performed as de-
scribed (Nishimura et al., 1994).
Production of monoclonal and polyclonal 8 antibodies
Balb/C mice were immunized by standard protocols with truncated se-
creted v8 according to the University of California at San Francisco
Committee on Animal Research guidelines. Splenocytes were fused with
SP 2/0 myeloma cells using commercial protocols (Boehringer). Clones
were screened by immunoprecipitation and flow cytometry to detect v8
(Nishimura et al., 1994). Antibodies were purified by ionic exchange chro-
matography using FPLC or used as supernatants for flow cytometry. Poly-
clonal anti-8 antiserum was generated and characterized as described
(Nishimura et al., 1998) by immunization of rabbits with a cytoplasmic
peptide (TRAVTYRREKPEEIKMDISK) corresponding to amino acids 740–
759 of the 8 ORF (BioSyn).
Fluorescence activated cell analysis, sorting, 
and immunocytochemistry
For FACS®, 8-expressing and mock-transduced cells were detached using
7 mM EDTA in DME, incubated with primary antibodies for 30 min at
4C, and detected with phycoerythrin-conjugated secondary antibodies
(Chemicon). Stained cells were analyzed using a FACsort® flow cytometer
and CellQuest software (Becton Dickinson). Immunofluorescence micros-
copy was performed essentially as described with the following modifica-
tions (Cambier et al., 2000). HT1080 cells transduced with either pBabe
Puro-8 or pBabe Puro underwent a second transduction with either
MT1-MMP–pLEGFP or pLEGFP and were selected with G418. LAP-1 was
used to coat glass chamber slides at a concentration of 10 g/ml, and cells
were allowed to attach to coated slides for 4 h before fixation. Antibodies
used were a polyclonal anti-8 antiserum and a monoclonal anti-GFP an-
tibody (CLONTECH Laboratories, Inc.). Secondary reagents were Alexa-
Fluor 595 goat anti–rabbit (Molecular Probes) and biotinylated sheep
anti–mouse (Amersham Pharmacia Biotech) followed by Oregon green
Streptavidin (Molecular Probes). Confocal images were obtained using a
Bio-Rad Laboratories MRC-1024 laser scanning confocal system and
LaserSharp2000 software (Bio-Rad Laboratories). Pseudocolored images
and composites were generated in Adobe Photoshop® (v. 6.0).
Immunoprecipitation, Western blotting, and zymography
8-expressing or mock-transduced cells in confluent 10-cm dishes were
either surface labeled with 125I, biotin, or were directly lysed in PBS with
1% Triton X-100 with 1 mM PMSF as described (Milner and Ffrench-Con-
stant, 1994; Nishimura et al., 1994). Immunoprecipitations and Western
blots were performed as described (Milner and Ffrench-Constant, 1994;
Nishimura et al., 1994). For LAP-1 degradation experiments, LAP-1 (10
g/ml) was added to individual wells of a 96-well plate containing 8-
overexpressing, MT1-MMP–, MT1-MMP–, or mock-transduced H1264
cells (4  104) in complete medium. For GM6001 and C1006 inhibition
experiments, 104 cells were added, and for RGD peptide blocking experi-
ments 2  104 cells were added. After a 12–16-h incubation, the medium
was collected and either added to TMLC reporter cells in the presence or
absence of recombinant TGF-1 (10 pM) or was subjected to 12.5% SDS-
PAGE and Western blotting as above. For zymography, cells were incu-
bated in serum-free media overnight in the presence or absence of pro–
MMP-2 (10 ng/well). Supernatants were harvested and loaded without
heating or reduction and resolved by 10% SDS-PAGE (1 mg/ml gelatin).
After three washes in 2.5% Triton X-100, the gels were incubated in sub-
strate buffer (50 mM Tris-HCL, 5 mM CaCl2, 0.01% NaN3, pH 8.0) and in-
cubated overnight at 37C. Lucent bands of gelatinolytic activity were
revealed by Coomassie staining. Digital images were acquired using East-
man Kodak Co. 1D 3.5.3 Imaging system. Composites were assembled in
Adobe Photoshop® (v. 6.0).
TGF- bioassay
To determine TGF- activation in a coculture assay, TMLC cells were cul-
tured with 8-expressing or mock-transduced cells in the presence or ab-
sence of anti–TGF-–blocking antibody (10 g/ml, 1D11; R&D Systems),
anti-8 (100 g/ml, 37E1) or anti-6 (150 g/ml, 10D5) as described (Abe
et al., 1994; Munger et al., 1999). To measure active TGF- in tumor tis-
sue, equal weights of tumors were minced and incubated in sterile DME
for 30 min at 4C. The supernatants containing active TGF- were har-
vested after centrifugation (20 g) at 4C. The pellets were then incubated in
serum-free DME for 20 min at 80C to activate SLC after which the super-
natants were harvested. The supernatants containing active or heat-acti-
vated (latent) TGF- were then added to preplated TMLC cells with or
without 1D11. For protease inhibitor assays, inhibitors were added at the
initiation of the coculture. The maximal dose of each inhibitor was defined
as the highest concentration that did not inhibit the ability of the TMLC
cells to respond to recombinant active TGF-. To measure soluble TGF-
activity from cultured cells, 106 HT1080 or SW480 cells, either 8-
expressing, 6-expressing, or mock-transduced, were incubated in 100 l of
complete medium with or without 37E1 or 10D5 for 1 h at 37C with gen-
tle rotation. Cell-free supernatants were harvested by centrifugation (20 g)
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for 5 min at 4C and then added to preplated TMLC cells in the presence or
absence of 1D11. For soluble receptor assays, conditioned medium ob-
tained from overnight cultures of 293 cells expressing truncated v8
(Nishimura et al., 1994, 1998) was used. Relative luciferase units were de-
fined as activity minus the background activity of the TMLC reporter cells.
In some experiments, the TMLC reporter cells themselves activated a small
amount of TGF- as determined by inhibition with anti–TGF-–blocking
antibodies. In these experiments when the test cells did not activate TGF-
the relative luciferase units (sample minus the TMLC background) were
less than zero.
Cell proliferation assays and lung tumor xenographs
Cell cycle analysis was performed as described previously (Cambier et al.,
2000) with the exception that some cells were treated overnight with 10
g/ml LAP-1. BrdU incorporation assays were performed as described
(Cambier et al., 2000). H647 tumor xenografts were established in nude
mice as described (Cambier et al., 2000), and experiments were performed
in full compliance with institutional guidelines and the University of Cali-
fornia at San Francisco Committee on Animal Research.
Statistical analysis
Student’s t test was used for comparison of two datasets; analysis of vari-
ance (ANOVA; for parametric data) or the Kruskal-Wallis test (for nonpara-
metric data) were used for more than two datasets. Tukey’s or Dunn’s test
was used for parametric or nonparametric data, respectively, to determine
where the differences lay. Significance was defined as p  0.05. Data are
shown as means 	 1 SEM unless otherwise noted. Statistical software used
was InStat v2.03 (GraphPad Software, Inc.).
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